Xtnac-AQ Injection contains Diclofenac 75 mg, a nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of acute pain, inflammation, and swelling associated with musculoskeletal disorders, postoperative pain, and other inflammatory conditions. Diclofenac exerts its therapeutic effect by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins, which are mediators of inflammation and pain. Xtnac-AQ Injection is administered intramuscularly or intravenously for rapid onset of action, providing effective relief in situations where oral administration is not feasible or when immediate analgesia is required. The dosage and duration of treatment should be individualized based on the severity of symptoms and patient response, with careful consideration of contraindications such as hypersensitivity to diclofenac, history of gastrointestinal bleeding or ulceration, and severe renal or hepatic impairment. Common adverse effects may include gastrointestinal discomfort, nausea, dizziness, and injection site reactions. Caution is advised in patients with cardiovascular risk factors due to potential increased risk of thrombotic events. Xtnac-AQ Injection should be used under medical supervision, adhering to recommended guidelines to minimize risks and ensure optimal therapeutic outcomes.